Clinical trials: Lower Urinary Tract Symptoms
Urinary Incontinence
Exploratory Study of a New Urine Collection Device for Men
The aim of the investigation is to evaluate the subjects experience of a new collection device for men. An open-labelled, single arm study design was chosen for this investigation with a duration of 1 week + up to 3 days extra.
- Trial name
- NCT04672993
- Testing
- Urine collection device for men
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Coloplast A/S
Overactive Bladder
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin
- Trial name
- FREEDOM (NCT00921245)
- Testing
- Darifenacin (Emselex, BAY79-4998)
- Where
- South Africa
- Volunteers
- 9 people
- Sponsor
- Bayer
Neurogenic Detrusor Overactivity, Overactive Bladder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
- Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron
- Trial name
- NCT02211846
- Testing
- Mirabegron
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 34 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Stress Urinary Incontinence
LIBERATE International
This is a prospective, randomized, double-blind, sham-controlled clinical study. The study is designed to demonstrate that active is superior to sham for the efficacy endpoints and is deemed to have appropriate safety as compared…
- Trial name
- NCT03619174
- Testing
- Viveve Treatment
- Where
- 6 sites in Canada
- Volunteers
- 99 people
- Sponsor
- Viveve Inc.
Overactive Bladder (OAB)
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT00742833
- Testing
- KUC-7483
- Where
- 6 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
BPH, Prostate Hyperplasia
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a…
- Conditions
- BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
- Trial name
- NCT03131544
- Testing
- MRI Guided Transrectal Periuretheral Transitional Zone Ablation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Prostate Laser Center, PLLC
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device.
- Trial name
- Omega (NCT05757687)
- Testing
- Omega device
- Where
- 5 sites in Georgia
- Volunteers
- 11 people
- Sponsor
- ProArc Medical
Prostatic Hyperplasia, Prostate
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.
- Trial name
- PILUTS (NCT00547625)
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Eli Lilly and Company
Vaginal Atrophy, Vulvovaginal Signs and Symptoms
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
The study is an open-label uncontrolled single-center study for the evaluation of the Performance characteristics (efficacy and safety) of the dermal filler "MMG-23-04-2019" on the female genital area for the medicinal…
- Conditions
- Vaginal Atrophy, Vulvovaginal Signs and Symptoms, Dyspareunia, Urinary Incontinence
- Trial name
- NCT04659668
- Testing
- MMG-23-04-2019
- Where
- Bulgaria
- Volunteers
- 37 people
- Sponsor
- Mesoestetic Pharma Group S.L.
Lower Urinary Tract Symptoms
Herbal Supplement Prosta-OK® Neo as an Adjunct Therapy in Patients With Mild to Severe Non-neurogenic Male Lower Urinary Tract Symptoms Receiving Tamsulosin Therapy
The aim of the study is to uses Prosta-OK® Neo that contains herb extracts including lycopene, phellinus linteus, pomegranate, pumpkin seed, selenium and zinc that have been demonstrated with functions of inhibiting 5-alpha…
- Trial name
- NCT04418635
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Acrobio Healthcare Inc.
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive…
- Trial name
- NCT02590250
- Testing
- botulinum toxin Type A
- Where
- 12 sites in India
- Volunteers
- 250 people
- Sponsor
- Allergan
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Stress Urinary Incontinence
Use of the Leva Incontinence System in Treating Bladder Incontinence.
This open-label proof-of-concept study is designed to evaluate the impact of the leva digital incontinence system on the treatment of stress and mixed urinary incontinence in women over a six week period.
- Trial name
- NCT03536923
- Testing
- Leva Incontinence System For Pelvic Floor Muscle strengthening
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Renovia, Inc.
Lower Urinary Tract Symptoms
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
The purpose of the this international, multicenter, randomised, single-blind, parallel group, Phase III study is to demonstrate that a single transrectal ultrasound (TRUS)-guided intraprostatic injection of NX-1207 provides a…
- Trial name
- NCT02003742
- Testing
- NX-1207, Tamsulosin
- Where
- 5 sites in Germany, Italy and 3 more
- Volunteers
- 104 people
- Sponsor
- RECORDATI GROUP
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.
The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the…
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause, Quality of Life
- Trial name
- STOPGSMP (NCT06962345)
- Testing
- Hormone-free vulvovaginal gel with the tested composition XCMIM20m
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Mucosa Innovations, S.L.
Urinary Bladder, Overactive
Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.
- Trial name
- SUNRISE (NCT00801944)
- Testing
- Solifenacin succinate
- Where
- 78 sites in Belgium, Czechia and 12 more
- Volunteers
- 973 people
- Sponsor
- Astellas Pharma Inc
Prostatic Hyperplasia
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate.
- Trial name
- NCT00457457
- Testing
- Tamsulosin, UK-369,003
- Where
- 46 sites in Australia, Belgium and 13 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Urinary Incontinence
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
This is a placebo-controlled, double-blind study to evaluate the safety and efficacy of two doses of DR-3001 in women with overactive bladder who have symptoms of predominant or pure urge incontinence, urinary urgency and…
- Trial name
- NCT00196404
- Testing
- DR-3001a, DR-3001b
- Where
- 48 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Duramed Research